Pyxis Oncology, Inc., is a preclinical oncology company. The Company is focused on developing an array of therapeutics to target cancers causing tumors cells. It also addresses the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company developed a portfolio of antibody drug conjugate (ADC), product candidates, and monoclonal antibody (mAb), preclinical discovery in combination with other therapies. The Company's ADC therapeutics attacks the drivers of tumor growth and progression within the tumor microenvironment (TME), including targeting of tumor antigens and modulating the innate and adaptive immune response. The TME is an immunosuppressive environment consisting of cancer cells and stroma, which includes the blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that surrounds the tumor. Its product candidate includes PYX-201, PYX-202 and PYX-203.